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A teenager presents to the gynecology clinic with vul-
var pruritus and edema. She complains of moderate pain
to touch. Previous treatments utilized for her complaints
include antifungals (topical and oral) and an antihista-
mine; the previous treatments did not provide relief.
The vulvar appearance is demonstrated in Figure 1
and Figure 2.
A perianal biopsy was performed. The histology is
demonstrated in Figure 3.














All of the following may be signs and symptoms of















The Home Study Course is intended for the prac-
ticing colposcopist or practitioner who is seeking to develop or
enhance his or her colposcopic skills. The goal of the course is
to present colposcopic cases that are unusual or instructive in
terms of appearance, presentation, or management or that
demonstrate new and important knowledge in the area of
colposcopy or pathology. Participants may benefit from read-
ing and studying the material or from testing their knowl-






The American Society for Colpos-
copy and Cervical Pathology (ASCCP) is accredited by the Ac-
 
creditation Council for Continuing Medical Education (ACCME)
to sponsor continuing medical education for physicians. The
ASCCP designates this continuing medical education activity
for 1 credit hour in Category 1 of the Physician’s Recognition
Award of the American Medical Association. Credit is avail-
able for those who choose to apply. The Home Study Course is
planned and produced in accordance with the ACCME’s 
 
Es-
sential Areas and Elements.
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a. No treatment needed
b. Isoniazid (INH), rifampin, pyrazinamide, etham-
butol, streptomycin
c. Sulfamethoxazole/trimethoprim (Bactrim®) alone
d. Metronidazole, ciprofloxacin, metronidazole plus
ciprofloxacin, infliximab (Remicade®), azathio-





a. Females more often than males
b. Males more often than females




Another patient is seen with the same underlying dis-
ease process.
Figure 4 demonstrates a:







Is there an increased risk of any form of cancer in pa-



















Crohn’s disease is a chronic inflammatory bowel dis-
ease. As many as 1 million Americans suffer from
Crohn’s disease. Up to 120,000 people per year are
diagnosed with moderate-to-severe disease. It most
often appears in the second to fourth decade of life.
Vulvar Crohn’s disease is rare. A diffuse lymphohis-
tiocytic infiltrate is present on histologic evaluation.
A loose noncaseating granuloma is seen. The absence
of caseation excludes tuberculosis. Stains for acid-
fast bacteria would be negative. While noncaseating
granulomas are seen in sarcoidosis, the presence of
giant cells in this patient excludes sarcoidosis. Giant
cells are numerous in Crohn’s disease, while sarcoi-
dosis has rare or no giant cells. Granuloma inguinale
is characterized by Donovan bodies on histology.





The most common symptoms of Crohn’s disease are
abdominal pain and cramping (lower right area), and
diarrhea, often following a meal. Rectal bleeding,
weight loss, joint pains and fever also may occur.
Anemia may be present. Some people find their symp-
toms are made worse by milk, alcohol, hot spices, or
fiber. Sores in the anal area occur. Sterile pyuria is not
seen in patients with Crohn’s disease. Fistulas may
form between the urinary structures and bowel, but
this would not be a sterile pyuria. Sterile pyuria may





The treatment of vulvar Crohn’s disease varies from
the usual gastrointestinal treatment regimen. Gener-
ally, metronidazole is used for initial treatment.
Ciprofloxacin also may be used as a single drug.
Metronidazole and ciprofloxacin may be combined
for better response, if needed. For resistant disease,
as well as for the treatment of open, draining fistulas,
Infliximab (Remicade®) may be used. Infliximab is
an anti-tumor necrosis factor (TNF), which is a pro-
tein produced by the immune system that may cause
the inflammation associated with Crohn’s disease.
Steroids and the 5-ASA drugs are generally effective
only for bowel disease rather than for perianal dis-
ease. Many patients with vulvar Crohn’s disease do
have bowel disease and require these drugs also. Immu-
nosuppressants, such as 6-mercaptopurine, and a re-
lated drug, azathioprine, may also be required at times.
Free radicals may contribute to the inflammation in
Crohn’s disease. The mineral zinc removes free radi-
cals from the bloodstream. Studies are under way to






Crohn’s disease affects males and females equally,
and it seems to run in some families. About 20% of
people with Crohn’s disease have a blood relative
with some form of irritable bowel disease, most often
a brother or sister and sometimes a parent or child. It
is interesting to note that this patient’s grandmother





A rectovaginal fistula is seen with a silver wire probe









required with failed medical therapy for Crohn’s dis-
ease and when fistulas such as this occur. It is impor-
tant to emphasize that Crohn’s disease is chronic and





Yes. There is an increased risk for cancer in patients
with colon involvement of Crohn’s disease (Crohn’s
colitis). There is a very small risk of small bowel adeno-
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Suggested Organizations and Web sites:
 
Crohn’s & Colitis Foundation of America, Inc., Na-
tional Headquarters, 386 Park Avenue South, 17th
Floor, New York, NY 10016-8804
http://www.ccfa.org
http://www.gastro.org
http://www.asge.org
http://content.health.msn.com/content/dmk/
dmk_article_5462267
http://www.healingwell.com/ibd/library/info1.htm#c6
http://www.virtualdrugstore.com/crohns/infliximab.html
